Adaptimmune Therapeutics plc
Home
Our Company
Overview
arrow_forward
Partners
arrow_forward
Board of Directors
arrow_forward
Leadership Team
arrow_forward
Scientific Advisory Board
arrow_forward
Pipeline
Clinical Pipeline
arrow_forward
Afami-cel
arrow_forward
ADP-A2M4CD8
arrow_forward
Preclinical Pipeline
arrow_forward
Technology
Overview
arrow_forward
Manufacturing
arrow_forward
Publications
arrow_forward
Patients & Families
Overview
arrow_forward
Taking Part in Our Clinical Trials
arrow_forward
Cancer Info
arrow_forward
Videos
arrow_forward
Engagement with Patient Organizations
arrow_forward
Clinical Trials
Overview
arrow_forward
Expanded Access Policy
arrow_forward
Investors & Media
Overview
arrow_forward
News Center
arrow_forward
Financial Info and Governance
arrow_forward
Stock Data
arrow_forward
SEC Filings
arrow_forward
Contact
Careers
Overview
arrow_forward
US Careers
arrow_forward
UK Careers
arrow_forward
Search
Annual Shareholder Meeting
Investors & Media
Investors & Media
Overview
News Center
Media
Corporate Presentations
Press Releases
Publications
Events
Email Alerts
Financial Info and Governance
General Meeting (merger)
Company Information
Leadership Team
Financial Results
Income Statement
Balance Sheet
Cash Flow
Board of Directors
Board Committees
Governance Documents
Annual Shareholder Meeting
FAQ
Contacts
Adaptimmune Ltd Report
Stock Data
Quote
Charts
Historical Data
Analyst Coverage
SEC Filings
Overview
All SEC Filings
Annual Reports
Quarterly Reports
Section 16 Filings
Financial Info and Governance
General Meeting (merger)
Company Information
Leadership Team
Financial Results
Income Statement
Balance Sheet
Cash Flow
Board of Directors
Board Committees
Governance Documents
Annual Shareholder Meeting
FAQ
Contacts
Adaptimmune Ltd Report
2023
picture_as_pdf
Notice of 2023 Annual General Meeting
picture_as_pdf
Annual Report (UK) 2022
picture_as_pdf
Form of Proxy (ordinary shareholder) 2023 AGM
picture_as_pdf
Definitive Proxy Statement
picture_as_pdf
10-K 2022
2022
picture_as_pdf
Notice of 2022 Annual General Meeting
picture_as_pdf
Annual Report (UK) 2021
picture_as_pdf
Form of Proxy (ordinary shareholder) 2022 AGM
picture_as_pdf
Definitive Proxy Statement
picture_as_pdf
10-K 2021
2021
picture_as_pdf
Notice of 2021 Annual General Meeting
picture_as_pdf
Annual Report (UK) 2020
picture_as_pdf
Form of Proxy (ordinary shareholder) 2021 AGM
picture_as_pdf
Definitive Proxy Statement
picture_as_pdf
10-K 2020
2020
picture_as_pdf
Notice of 2020 Annual General Meeting
picture_as_pdf
Annual Report (UK) (year ended 31 December 2019)
picture_as_pdf
Chairman Letter for 2020 AGM
picture_as_pdf
Form of Proxy (ordinary shareholder) 2020 AGM
picture_as_pdf
Definitive Proxy Statement
picture_as_pdf
10-K 2019
2019
picture_as_pdf
Notice of 2019 Annual General Meeting
picture_as_pdf
Annual Report (UK) (year ended 31 December 2018)
picture_as_pdf
Chairman Letter for 2019 AGM
picture_as_pdf
Form of Proxy (ordinary shareholder) 2019 AGM
picture_as_pdf
Definitive Proxy Statement
picture_as_pdf
10-K 2018
2018
picture_as_pdf
Notice of 2018 Annual General Meeting
picture_as_pdf
Chairman Letter for 2018 AGM
picture_as_pdf
Form of Proxy (ordinary shareholder) 2018 AGM
picture_as_pdf
Annual Report (UK) (year ended 31 December 2017)
picture_as_pdf
Definitive Proxy Statement
picture_as_pdf
10-K 2017
2017
picture_as_pdf
Annual Report (UK) (year ended 31 December 2016)
picture_as_pdf
Form of Proxy (ordinary shareholder) 2017 AGM
picture_as_pdf
Chairman Letter for 2017 AGM
picture_as_pdf
Notice of 2017 Annual General Meeting
picture_as_pdf
Definitive Proxy Statement
picture_as_pdf
10-K 2016
2016
picture_as_pdf
Notice of 2016 Annual General Meeting
picture_as_pdf
Annual Report (UK) (period ended 31 December 2015)
picture_as_pdf
Articles of Association (redline of proposed amends)
picture_as_pdf
Proposed new Articles of Association
2015
picture_as_pdf
Notice of 2015 Annual General Meeting
picture_as_pdf
Annual Report (UK) (period ended 30 June 2015)